AnaptysBio Inc (ANAB)vsModerna Inc (MRNA)
ANAB
AnaptysBio Inc
$50.50
+1.75%
HEALTHCARE · Cap: $1.39B
MRNA
Moderna Inc
$214.17
+2.98%
HEALTHCARE · Cap: $87.04B
Smart Verdict
WallStSmart Research — data-driven comparison
Moderna Inc generates 2000% more annual revenue ($2.23B vs $106.09M). ANAB leads profitability with a 247.0% profit margin vs -141.4%. ANAB earns a higher WallStSmart Score of 46/100 (D+).
ANAB
Hold46
out of 100
Grade: D+
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+65.6%
Fair Value
$160.49
Current Price
$50.50
$109.99 discount
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$214.16
$79.45 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 247 of every $100 in revenue as profit
Strong operational efficiency at 53.4%
Revenue surging 23.5% year-over-year
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Trading at 140.3x book value
ROE of -210.1% — below average capital efficiency
Trading at 12.6x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ANAB
The strongest argument for ANAB centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 247.0% and operating margin at 53.4%. Revenue growth of 23.5% demonstrates continued momentum.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : ANAB
The primary concerns for ANAB are EPS Growth, Market Cap, Price/Book. Debt-to-equity of 25.47 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
ANAB profiles as a growth stock while MRNA is a turnaround play — different risk/reward profiles.
MRNA carries more volatility with a beta of 1.09 — expect wider price swings.
ANAB is growing revenue faster at 23.5% — sustainability is the question.
ANAB generates stronger free cash flow (-27M), providing more financial flexibility.
Bottom Line
ANAB scores higher overall (46/100 vs 21/100), backed by strong 247.0% margins and 23.5% revenue growth. MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AnaptysBio Inc
HEALTHCARE · BIOTECHNOLOGY · USA
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?